2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2477

Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures
Abstract Number: 2478

Do Age and Education Influence the Disease Activity Score? an Explorative Analysis in the Norwegian Register of Dmards
Abstract Number: 2479

Pilot Study of Characterizing Rheumatoid Arthritis Related Morning Stiffness
Abstract Number: 2480

Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Abstract Number: 2481

Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
Abstract Number: 2482

The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients
Abstract Number: 2483

Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Abstract Number: 2484

Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Abstract Number: 2485

Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Abstract Number: 2486

Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Abstract Number: 2487

Comparison of QOL Evaluation Using EQ-5D-3L and EQ-5D-5L in Japanese RA Patients: A Study Using the IORRA Cohort
Abstract Number: 2488

Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
Abstract Number: 2489

In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Abstract Number: 2490

Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?
Abstract Number: 2491

Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].